About Us Locations Disclaimer

Dr. R. deGoma

Home
Prevention 2011
Who Needs Prevention
Benefits of Prevention
Risk Assessment
Advanced Lipid Therapy
Stent vs Medical Therapy
Specialized Center
Performance Data
Employer Mandate
Employee Prevention
Patient Mentoring
Coronary Calcium Score
Women & Heart Disease
NJPreventiveCardiology.com

 

Click here for NJ Preventive Cardiology practice brochure

 

Mentoring Program

The Million Hearts Initiative

For Physicians:

Practical Tips for Clinicians

For Communities:

Heart2Heart Talk

For Employers and Employees: You and Health Reform

     

Prevention, Diagnosis and Treatment of Heart Disease & Cardiovascular Risk Factors

Rolando L. deGoma, M.D., F.A.C.C., F.N.L.A.

                                 Medical Director

Board Certification:

American Board of Clinical Lipidology 2005

American Board of Cardiovascular Disease 1979

American Board of Internal Medicine 1977

Brief Description of the Practice:

We provide a complete range of services from prevention to diagnosis to treatment of heart disease and cardiovascular risk factors. After a decade of clinical experience in aggressive cholesterol therapy and cardiovascular risk management, it became clear to Dr. deGoma that most heart attacks, strokes, heart bypasses, stents and heart failures can be prevented, and those not preventable, can be delayed by years or decades. Using a goal-oriented clinical management system, we were able to achieve the best published performance data in the US with 85% of high risk patients at LDL goal, with more patients having LDL-c less than 50 than over 130 mg/dl. This high treatment success rate translates to improved patient outcomes and reduced utilization of expensive healthcare resources. Placebo-controlled clinical trials have demonstrated about 40% total event reductions during the duration of the trials, everywhere between 2 to 5 years. Duration of treatment in clinical practice does not have the time constraint of clinical trials, and after a decade of aggressive prevention in our practice, the total event reduction that we witnessed exceeds those reported in clinical trials.

Areas of Interest:

atherosclerosis stabilization and disease regression, advanced cholesterol management, chest pain, corporate employee heart attack and stroke prevention program, Million Hearts Initiative, delivering care innovations, process of care improvement   


Websites: www.deGomaMD.com, www.NJPreventiveCardiology.com

Main Office: 416 Bellevue Avenue, Suite 303, Trenton, NJ 08618  Click here for google map.

Satellite Office: 1445 Whitehorse-Mercerville Rd., Suite 109, Hamilton, NJ 08690  Click here for google map.

Phone: 609-396-6363

Fax: 609-695-7747

Email: RdeGomaMD@gmail.com

Office Manager: Kathy Madola
Office Hours: 9:00 am - 4:00 pm Mon, Wed, Thurs, Friday

Insurance accepted: Medicare, Blue Cross-Blue Shield, Aetna, United Healthcare, Oxford and other major insurance carriers.

BIOGRAPHICAL SKETCH, EXPERTISE AND SPECIAL INTEREST

Dr. R. deGoma was recently featured in the National Lipid Association's Member Spotlight. He talked about his personal and professional journey to prevention which began in 2001 and how it changed the way he practices cardiology. Seeing the impact of aggressive lipid therapy in halting the normal progressive course of CHD after a decade of aggressive evidenced-based preventive therapies, he concluded that prevention is the missing component of cardiac care. To read more, please click here.

In 2005, he became one of the less than 20 board certified cardiologists who became board certified Clinical Lipidologist. The wide treatment gap is a particular interest for Dr. deGoma. In the L-TAP study was published in 2000, only 18% of CHD patients were treated to LDL-c target of less than 100 mg/dl. 82% were not at goal, either not treated adequately or not treated at all. Dr. deGoma participated in a similar study and found that cardiologists had a similar problem.

For several years, he worked on a clinical management system for his private practice. In 2006, he published and presented his clinic data at the annual national scientific meeting SGIM in Los Angeles. In his practice, using the clinical management system that he developed, 85% of CHD and CHD risk equivalent patients were treated to LDL goal of less than 100 mg/dl. Only 15% were not at goal. There were more patients with LDL below 50 mg/dl than patients with LDL over 130 mg/dl. He is the only preventive cardiologist in the US with published performance data. To read more, please click here.

RECENT PUBLICATIONS

deGoma RL, deGoma EM. A practical, office-based cholesterol management system. Journal of General Internal Medicine 2006 Apr; 21(S4)

deGoma EM, deGoma RL, Rader DJ. Beyond HDL-C Levels: Evaluating HDL function as influenced by pharmacotherapy. J Am Coll Cardiol 2008

 

On a personal note

 

    WebHeartMD Journal

     2011

 

       

    My Cosmos...

            here & there..

       2011

 

 

Emil M. deGoma, MD, FACC

Medical Director,

UPenn Preventive Cardiovascular  Program

Health Premium Discount

Lower your risk for heart attack and stroke using evidence-based therapies and become eligible for a substantial premium discount by 2014.
Health Reform 2010
Prevention and Wellness Summary Provisions
Relay Health
Contact Office for Non-Urgent Matters

 

We Support Million Hearts Initiative

 

497,470 Preventable CHD Deaths Annually with Evidence-based Medical Therapy

 

JAMA: 38% of Nonacute Stents Called into Question

 

Optimal Medical Therapy Still Underused in CHD

 

Legacy Effects of Statin Therapy - Reduction in All-Cause Mortality

 

SG2 Expert Talks About Resetting Priorities in Cardiology

 

AHA: Get With The Guidelines - Not Much Improvement

 

AIM-HIGH Trial - Take Home Message

 

    
www.deGomaMD.com
Copyright 2001-2011     Preventing Most Heart Attacks and Strokes since 2001     eMedical Consulting     All rights reserved